menu
    • menu

    Company profile for Eikonoklastes Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eikonoklastes Therapeutics has licensed and is developing a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem ...
    Eikonoklastes Therapeutics has licensed and is developing a state of the art immune conjugate technology targeting tissue factor for the treatment of solid tumors and other pathologic conditions. The immune conjugate is engineered with a natural high affinity ligand for tissue factor, conjugated to an IgG3 Fc. This allows the compound to bind to the tumor cells, neovasculature supplying blood to the tumors, and the tumor stem cells, to trigger complement activation (CDC) and antibody dependent cellular cytotoxicity (ADCC) killing of the pathologic cells. This approach is expected to provide potency and selectivity with minimal side effects.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eikonoklastes TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    981 HILL STREET,CINCINNATI
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eikonoklastes.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eikonoklastes-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eikonoklastes Announces Formation of Scientific Advisory Board – Gene Therapy
    Eikonoklastes Announces Formation of Scientific Advisory Board – Gene Therapy

    15 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230515005518/en

    BUSINESSWIRE
    15 May 2023
    Share Share
    Eikonoklastes and Forge Biologics Announce Viral Vector Contract Development
    Eikonoklastes and Forge Biologics Announce Viral Vector Contract Development

    29 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221129005440/en

    BUSINESSWIRE
    29 Nov 2022
    Share Share
    Eikonoklastes Receives FDA Orphan Drug Designation for 1st-in-class (ALS)
    Eikonoklastes Receives FDA Orphan Drug Designation for 1st-in-class (ALS)

    09 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221108005511/en

    BUSINESSWIRE
    09 Nov 2022
    Share Share
    Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy
    Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy

    19 Jan 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220119005338/en

    BUSINESSWIRE
    19 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search